How many drugs treat Upper respiratory infection?

Drug Landscape tracks 6 marketed treatments for Upper respiratory infection (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/upper-respiratory-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Upper respiratory infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Upper respiratory infection (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Upper respiratory infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Cefradex	cefradine	Bristol-Myers Squibb	cefradine	Matrix metalloproteinase-9	1974-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM
Phenoxymethylpenicillin	Phenoxymethylpenicillin	Katarina Hedin		Bacterial penicillin-binding protein, Penicillin-binding protein 1A
Cephradin	Cephradin	Sohag University		Matrix metalloproteinase-9, Somatostatin receptor type 4, Bacterial penicillin-binding protein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Upper respiratory infection
Bristol-Myers Squibb · 1 drug in Upper respiratory infection
Karlstad University · 1 drug in Upper respiratory infection
Katarina Hedin · 1 drug in Upper respiratory infection
Pfizer · 1 drug in Upper respiratory infection
Sohag University · 1 drug in Upper respiratory infection
Teva Pharmaceuticals USA · 1 drug in Upper respiratory infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Upper respiratory infection:

Cite this brief

Drug Landscape (2026). Upper respiratory infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/upper-respiratory-infection. Accessed 2026-06-10.

Upper respiratory infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing